Disufenton sodium

Disufenton sodium

File:Disufenton sodium.png
Systematic (IUPAC) name
Disodium 4-[(Z)-(tert-butyl-oxidoazaniumylidene)methyl]benzene-1,3-disulfonate
Identifiers
ATC code	none
PubChem	CID: 6440181
ChemSpider	28530805
UNII	7M1J3HN9VO N
KEGG	D03875 Y
ChEMBL	CHEMBL1627056 N
Chemical data
Formula	C11H13NNa2O7S2
Molecular mass	381.33 g/mol
SMILES CC(C)(C)[N+](=Cc1ccc(cc1S(=O)(=O)[O-])S(=O)(=O)[O-])[O-].[Na+].[Na+]
InChI InChI=1S/C11H15NO7S2.2Na/c1-11(2,3)12(13)7-8-4-5-9(20(14,15)16)6-10(8)21(17,18)19;;/h4-7H,1-3H3,(H,14,15,16)(H,17,18,19);;/q;2*+1/p-2 Key:XLZOVRYBVCMCGL-UHFFFAOYSA-L
NY (what is this?)  (verify)

Disufenton sodium (NXY-059, Cerovive) is the disulfonyl derivative of the neuroprotective spin trap phenylbutylnitrone or "PBN". It was under development at the drug company AstraZeneca. A 2005 phase-3 clinical trial called "SAINT-1" reported some efficacy in the acute treatment of ischemia injury due to stroke. However, a 2006 attempt to repeat this trial indicated no significant activity. After ruling out other causes, the authors tentatively attributed the positive results in the first trial to "chance". AstraZeneca then terminated the development programme. PBN and its derivatives hydrolyze and oxidize in vitro to form respectively MNP-OH ( AKA, NtBHA ) and its parent spin-trap MNP.

External links

• Oxidants, antioxidants and the ischemic brain
• NXY-059: Review of Neuroprotective Potential for Acute Stroke